CO6210756A2 - La proteina linfopoyetina estromal timica canina y usos de la misma - Google Patents

La proteina linfopoyetina estromal timica canina y usos de la misma

Info

Publication number
CO6210756A2
CO6210756A2 CO09062338A CO09062338A CO6210756A2 CO 6210756 A2 CO6210756 A2 CO 6210756A2 CO 09062338 A CO09062338 A CO 09062338A CO 09062338 A CO09062338 A CO 09062338A CO 6210756 A2 CO6210756 A2 CO 6210756A2
Authority
CO
Colombia
Prior art keywords
tslp
seq
protein
amino acid
antigenic fragment
Prior art date
Application number
CO09062338A
Other languages
English (en)
Spanish (es)
Inventor
Jeanine Mattson
Daniel Gorman
Waal Malefyt Rene De
Mohamad A Morsey
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of CO6210756A2 publication Critical patent/CO6210756A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CO09062338A 2006-12-14 2009-06-16 La proteina linfopoyetina estromal timica canina y usos de la misma CO6210756A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87513506P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
CO6210756A2 true CO6210756A2 (es) 2010-10-20

Family

ID=39430681

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09062338A CO6210756A2 (es) 2006-12-14 2009-06-16 La proteina linfopoyetina estromal timica canina y usos de la misma

Country Status (18)

Country Link
US (3) US7718772B2 (enExample)
EP (1) EP2104683B1 (enExample)
JP (4) JP2010512744A (enExample)
KR (1) KR101525631B1 (enExample)
CN (2) CN102584998B (enExample)
AU (1) AU2007334531B2 (enExample)
BR (1) BRPI0720001A2 (enExample)
CA (1) CA2671865C (enExample)
CO (1) CO6210756A2 (enExample)
ES (1) ES2582655T3 (enExample)
IL (2) IL199170A (enExample)
IN (1) IN2009CN03372A (enExample)
MX (1) MX2009006470A (enExample)
NZ (1) NZ578352A (enExample)
RU (2) RU2457217C2 (enExample)
UA (3) UA120027C2 (enExample)
WO (1) WO2008076255A2 (enExample)
ZA (1) ZA200904152B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120027C2 (uk) 2006-12-14 2019-09-25 Шерінг-Плау Лтд. Ізольоване антитіло проти собачого тимусного стромального лімфопоетину (tslp)
JP5492158B2 (ja) 2011-08-24 2014-05-14 富士フイルム株式会社 ヒトtsh及び犬tshに対する抗体
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
AR090915A1 (es) * 2012-05-04 2014-12-17 Intervet Int Bv Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg
US20160052985A1 (en) * 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
MY177098A (en) * 2013-08-09 2020-09-05 Astellas Pharma Inc Novel anti-human tslp receptor antibody
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
EP3954710A3 (en) 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
ES3014160T3 (en) 2015-12-18 2025-04-21 Intervet Int Bv Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
CN115028722B (zh) * 2021-03-05 2024-09-03 拜西欧斯(北京)生物技术有限公司 抗tslp抗体及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2349762C (en) 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
EP1651247B1 (en) * 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
EP1786826A4 (en) * 2004-07-28 2008-04-23 Tanox Inc THYMIC STROMAL LYMPHOPOIETINE PROMOTER AND USE THEREOF
SE532251C2 (sv) 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
UA120027C2 (uk) 2006-12-14 2019-09-25 Шерінг-Плау Лтд. Ізольоване антитіло проти собачого тимусного стромального лімфопоетину (tslp)

Also Published As

Publication number Publication date
CN101631800B (zh) 2012-12-05
JP2015107121A (ja) 2015-06-11
CA2671865A1 (en) 2008-06-26
RU2009126617A (ru) 2011-01-20
US8076456B2 (en) 2011-12-13
RU2457217C2 (ru) 2012-07-27
RU2617957C2 (ru) 2017-04-28
CN101631800A (zh) 2010-01-20
MX2009006470A (es) 2009-06-26
US7718772B2 (en) 2010-05-18
AU2007334531A1 (en) 2008-06-26
KR101525631B1 (ko) 2015-06-04
UA108064C2 (uk) 2015-03-25
US8791242B2 (en) 2014-07-29
IN2009CN03372A (enExample) 2015-08-07
ZA200904152B (en) 2011-11-30
CA2671865C (en) 2017-01-10
CN102584998B (zh) 2017-07-04
WO2008076255A2 (en) 2008-06-26
AU2007334531B2 (en) 2012-04-12
JP5707380B2 (ja) 2015-04-30
JP2013048637A (ja) 2013-03-14
RU2012113162A (ru) 2013-10-20
US20080152620A1 (en) 2008-06-26
UA120027C2 (uk) 2019-09-25
US20130183291A1 (en) 2013-07-18
KR20090097921A (ko) 2009-09-16
WO2008076255A3 (en) 2008-09-18
UA95329C2 (ru) 2011-07-25
CN102584998A (zh) 2012-07-18
EP2104683A2 (en) 2009-09-30
US20110033478A1 (en) 2011-02-10
JP2010512744A (ja) 2010-04-30
EP2104683B1 (en) 2016-05-25
IL215507A0 (en) 2011-11-30
JP6117767B2 (ja) 2017-04-19
NZ578352A (en) 2012-05-25
ES2582655T3 (es) 2016-09-14
JP2012090647A (ja) 2012-05-17
BRPI0720001A2 (pt) 2013-12-24
IL199170A (en) 2015-04-30

Similar Documents

Publication Publication Date Title
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
AR061894A1 (es) Vacunas para malaria
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
MX2015013065A (es) Proteinas f de rsv de prefusion y su uso.
PE20071055A1 (es) Anticuerpos anti mn
CL2021002727A1 (es) Vacuna con subunidades del vfpc
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
MX2015012825A (es) Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
MX2019005137A (es) Vacuna contra parvovirus porcino.
EA201391548A1 (ru) Иммуногенная композиция
ES2565757T3 (es) Vacuna de PCSK9
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
PE20081687A1 (es) Proteina de fusion
EA201491123A1 (ru) Субъединичная вакцина против цирковируса свиней типа 2 (pcv2)
MX2021008035A (es) Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
CO2021005069A2 (es) Vacuna de ibv h52 con proteína espicular heteróloga
EA201690115A1 (ru) Комбинированные иммуногенные композиции
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
PE20252772A1 (es) Anticuerpo que se une al dominio similar a la proteasa del receptor de transferrina humano htfr1
AR080621A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria

Legal Events

Date Code Title Description
FC Application refused